Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PAS-004 by Pasithea Therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease): Likelihood of Approval
PAS-004 is under clinical development by Pasithea Therapeutics and currently in Phase I for Neurofibromatoses Type I (Von Recklinghausen's Disease)....
Data Insights
PAS-004 by Pasithea Therapeutics for Solid Tumor: Likelihood of Approval
PAS-004 is under clinical development by Pasithea Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...